Analysis of oncology research from 2001 to 2010: a scientometric perspective

Shao,Hongfang; Yu,Qi; Bo,Xiaoming; Duan,Zhiguang

doi:10.3892/or.2013.2239

Analysis of oncology research from 2001 to 2010: a scientometric perspective

Authors:
- Hongfang Shao
- Qi Yu
- Xiaoming Bo
- Zhiguang Duan
View Affiliations

Affiliations: School of Public Health, Shanxi Medical University, Taiyuan 030001, P.R. China, Department of Information Management, Shanxi Medical University, Taiyuan 030001, P.R. China
Published online on: January 17, 2013 https://doi.org/10.3892/or.2013.2239
Pages: 1441-1452

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Over the past half-century, the incidence of tumours has increased, resulting in cancer becoming one of the most lethal diseases in humans. In the present study, we elucidated the status of oncology research from 2001 to 2010. Studies published in 30 representative oncology journals were retrieved from the Web of Science (2001-2010) to compose our dataset. Knowledge domain visualisation, co-citation analysis and social network analysis methods were used. By mapping the oncology research performed from 2001 to 2010, we identified the primary research centres, including the top 20 institutions and countries and the 4 major oncology research fronts: i) the mechanism of abnormal oncogene expression; ii) tumour metastasis and angiogenesis; iii) the relationship between cancer cells and apoptosis; and iv) tumour vaccines. We also identified the 36 most collaborative academic communities, and multiple myeloma, angiogenesis and acute lymphocytic leukaemia were found to be the focuses of collaborative research in oncology from 2001 to 2010. Over the past 10 years, America has led oncology research, while China is the sole developing country to be ranked in the top 10. Analyses of the main research centres and forefronts may assist researchers in addressing these forefronts and ascertaining the developing trends in oncology. Analysis of the academic communities performing oncology research may provide scientific evidence and suggestions for policymakers to select the most prolific academic groups and leaders and to effectively manage and finance future oncology research. These selected groups and individuals will carry out additional joint undertakings and solve complex problems encountered in oncology research.

View Figures

View References

1	Borner K, Chen CM and Boyack KW: Visualizing knowledge domains. Annu Rev Inf Sci Technol. 37:179–255. 2003. View Article : Google Scholar
2	Chen Y and Liu ZY: The rise of mapping knowledge domain. Studies in Science of Science. 23:149–154. 2005.
3	Jankovic MP, Kaufmann M and Kindler CH: Active research fields in anesthesia: a document co-citation analysis of the anesthetic literature. Anesth Analg. 5:1524–1533. 2008. View Article : Google Scholar : PubMed/NCBI
4	Jarneving B: A comparison of two bibliometric methods for mapping of the research front. Scientometrics. 2:245–263. 2005. View Article : Google Scholar
5	Lee MR and Chen TT: Revealing research themes and trends in knowledge management: from 1995 to 2010. Knowledge-Based System. 28:47–58. 2012. View Article : Google Scholar
6	Zhao R and Wang J: Visualizing the research on pervasive and ubiquitous computing. Scientometrics. 86:593–612. 2011. View Article : Google Scholar
7	Chen CM, McCain K, White H and Lin X: Mapping Scientometrics (1981–2001). In: Proc 65th Asist Annual Meeting; 39. pp. 25–34. 2002
8	An XY and Wu QQ: Co-word analysis of the trends in stem cell field based on subject heading weighting. Scientometrics. 88:133–144. 2011. View Article : Google Scholar
9	Chen CM: CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 57:359–377. 2006. View Article : Google Scholar
10	Chen C, Ibekwe-San Juan F and Hou J: The structure and dynamics of cocitation clusters: a multiple-perspective cocitation analysis. J Am Soc Inf Sci Technol. 61:1386–1409. 2010. View Article : Google Scholar
11	Chen CM: Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA. 101:5303–5310. 2004. View Article : Google Scholar : PubMed/NCBI
12	Chen CM, Cribbin T, Macredie R and Morar S: Visualizing and tracking the growth of competing paradigms: two case studies. J Am Soc Inf Sci Technol. 53:678–689. 2002. View Article : Google Scholar
13	Chen C, Hu Z, Liu S and Tseng H: Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 12:593–608. 2012. View Article : Google Scholar : PubMed/NCBI
14	Small H: Co-citation in the scientific literature: a new measure of the relationship between two documents. J Am Soc Info Sci. 24:265–269. 1973. View Article : Google Scholar
15	Liu Z, Chen Y and Chen H: Mapping Knowledge Domains Methods and Application. 1st edition. People Publishing House; Peking: pp. 34–81. 2008
16	Liu J: An introduction to Social Network Analysis. 1st edition. Social Science Academic Press; (China), Beijing: pp. 4–25. 2004
17	Katz JS and Martin BR: What is research collaboration? Res Policy. 26:1–18. 1997. View Article : Google Scholar
18	Gossart C and Ozman M: Co-authorship networks in social sciences: the case of Turkey. Scientometrics. 78:323–345. 2009. View Article : Google Scholar
19	Lu HY and Feng YQ: A measure of authors’ centrality in co-authorship networks based on the distribution of collaborative relationships. Scientometrics. 81:499–511. 2009.
20	Yu Q, Shao H and Duan Z: Research groups of oncology co-authorship network in China. Scientometrics. 89:553–567. 2011. View Article : Google Scholar
21	Morel CM, Serruya SJ, Penna GO and Guimarães R: Co-authorship network analysis: a powerful tool for strategic planning of research, development and capacity building programs on neglected diseases. PLoS Negl Trop Dis. 3:82009. View Article : Google Scholar
22	Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, Papadopolous N, Peltomäki P, de la Chapelle A, Hamilton SR, Kinzler KW and Vogelstein B: Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 9:48–55. 1995. View Article : Google Scholar : PubMed/NCBI
23	Issa JP, Baylin SB and Herman JG: DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 11:S7–S11. 1997.PubMed/NCBI
24	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
25	Sun C and Wang H: The role of SNAIL gene in gynecologic cacinoma metastasis mechanism. J Int Obstet Gynecol. 4:260–263. 2010.
26	Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:422–426. 1999. View Article : Google Scholar : PubMed/NCBI
27	Sionov RV and Haupt Y: The cellular response to p53: the decision between life and death. Oncogene. 45:6145–6157. 1999. View Article : Google Scholar : PubMed/NCBI
28	Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu XB, Soron G, Cooper B, Brayton C, Park SH, Thompson T, et al: p53 mutant mice that display early ageing-associated phenotypes. Nature. 415:45–53. 2002. View Article : Google Scholar : PubMed/NCBI
29	Bond GL, Hu WW, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G and Levine AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
30	Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S and Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science. 279:349–352. 1998. View Article : Google Scholar : PubMed/NCBI
31	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
32	Guo QS and Liu YX: Lung cancer target to treatment medicine progress. World Clin Drugs. 5:282–285. 2005.
33	Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon T, Naoki K, Sasaki H, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
34	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
35	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
36	Shi W and Li JS: Clinical significance of the expression of ADAM9 in colon carcer. J Southeast University (Medical Science Edition). 4:274–278. 2009.
37	Kerr JF, Wyllie AH and Currie AR: Apoptosis-basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:239–257. 1972. View Article : Google Scholar : PubMed/NCBI
38	Liu LJ, Peng JX, Hong HZ, Ye W and Qiao YY: Mitochondrial changes and role in apoptosis. Chin J Cell Biol. 27:117–120. 2005.
39	Green DR and Kroemer G: The pathophysiology of mitochondrial cell death. Science. 305:626–629. 2004. View Article : Google Scholar : PubMed/NCBI
40	Deng C and Shao ZW: Apoptosis of osteosarcoma cells induced by a combination of TRAIL, adriamycin and IFN-γ. Cancer Res Prev Treat. 1:1–4. 2010.PubMed/NCBI
41	Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, et al: Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999. View Article : Google Scholar : PubMed/NCBI
42	Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Masters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
43	Cao ZA, Daniel D and Hanahan D: Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer. 2:112002. View Article : Google Scholar : PubMed/NCBI
44	Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 4:321–327. 1998. View Article : Google Scholar : PubMed/NCBI
45	Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J and Sy MS: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science. 263:518–520. 1994. View Article : Google Scholar : PubMed/NCBI
46	He TC, Chan TA, Vogelstein B and Kinzler KW: PPAR delta is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell. 99:335–345. 1999. View Article : Google Scholar : PubMed/NCBI
47	Collado M, Blasco MA and Serrano M: Cellular senescence in cancer and aging. Cell. 130:223–233. 2007. View Article : Google Scholar : PubMed/NCBI
48	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
49	Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
50	Blann AD, Lip GY, Islim IF and Beevers DG: Evidence of platelet activation in hypertension. J Hum Hypertens. 11:607–609. 1997. View Article : Google Scholar : PubMed/NCBI
51	Chou JJ, Li HL, Salvesen GS, Yuan JY and Wagner G: Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell. 96:615–624. 1999. View Article : Google Scholar : PubMed/NCBI
52	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 144:646–674. 2000. View Article : Google Scholar
53	Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
54	Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
55	Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3 Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 401:616–620. 1999. View Article : Google Scholar : PubMed/NCBI
56	Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Sambrook J, et al: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 94:205–215. 2002. View Article : Google Scholar : PubMed/NCBI